Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing

Rhea-AI Filing Summary

Coherus Oncology, Inc. ownership update: Thomas A. Satterfield, Jr. reports beneficial ownership of 6,930,000 shares, equal to 4.6% of the company's common stock. The filing cites 149,889,902 shares outstanding as of February 28, 2026 per the issuer's Form 10-K. The reported holdings combine sole and shared voting/dispositive power and include shares held jointly, by related entities (Tomsat Investment & Trading Co., Inc.; Caldwell Mill Opportunity Fund; A.G. Family L.P.) and multiple limited powers of attorney for other holders.

Key Figures

Beneficially owned shares: 6,930,000 shares Percent of class: 4.6% Shares outstanding: 149,889,902 shares +2 more

5 metrics

Beneficially owned shares 6,930,000 shares Total reported beneficial ownership in the Schedule 13G/A

Percent of class 4.6% Percent of common stock represented by 6,930,000 shares

Shares outstanding 149,889,902 shares Shares outstanding as of February 28, 2026 per the issuer's Form 10-K

Sole voting power 865,000 shares Shares with sole voting power reported on the cover page

Shared voting power 6,065,000 shares Shares with shared voting power reported on the cover page

Key Terms

Beneficial ownership, Sole/Shared voting power, Limited power of attorney, Percent of class

4 terms

Beneficial ownership regulatory

"Amount beneficially owned: Incorporated by reference from Item 9 of the Cover Page."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole/Shared voting power regulatory

"Sole Voting Power 865,000.00 | Shared Voting Power 6,065,000.00"

Limited power of attorney legal

"Mr. Satterfield has limited powers of attorney for voting and disposition purposes with respect to the following shares:"

Percent of class regulatory

"4.6 % | Comment for : * Based on 149,889,902 shares of common stock"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 09:02 PM Learn about SEC filing dates

FAQ

What percentage of Coherus Oncology (CHRS) does Thomas A. Satterfield, Jr. own?

He reports beneficial ownership of 4.6% of Coherus Oncology's common stock. This percentage is calculated using 149,889,902 shares outstanding as of February 28, 2026, as cited in the company's Annual Report on Form 10-K.

How many Coherus Oncology shares does Thomas A. Satterfield, Jr. beneficially own?

The filing shows 6,930,000 shares beneficially owned by Mr. Satterfield. The total combines shares with sole and shared voting/dispositive power across individual, corporate, fund, and partnership holdings disclosed in the schedule.

Which entities or relationships account for Satterfield's reported holdings in CHRS?

Reported holdings include 115,000 shares held jointly with his spouse, 800,000 shares via Tomsat Investment & Trading Co., Inc., 2,100,000 shares via Caldwell Mill Opportunity Fund, and 1,750,000 shares via A.G. Family L.P., plus other positions under limited powers of attorney.

Does the Schedule 13G/A disclose voting or dispositive power details for the CHRS position?

Yes. The filing lists 865,000 shares as sole voting (and sole dispositive) power and 6,065,000 shares as shared voting (and shared dispositive) power, which together correspond to the reported 6,930,000 shares beneficially owned.

Are there shares covered by powers of attorney in the CHRS 13G/A filing?

Yes. The filing enumerates limited powers of attorney over multiple accounts totaling several hundred thousand shares, including 400,000 (Thomas A. Satterfield, Sr.) and other named holders, reflecting delegated voting/disposition authority for those shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Coherus Oncology, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

19249H103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19249H103

1

Names of Reporting Persons

Thomas A. Satterfield, Jr.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 865,000.00
6	Shared Voting Power 6,065,000.00
7	Sole Dispositive Power 865,000.00
8	Shared Dispositive Power 6,065,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,930,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: * Based on 149,889,902 shares of common stock of the issuer outstanding as of February 28, 2026, as reported by the issuer on its Annual Report on Form 10-K for the year ended December 31, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coherus Oncology, Inc.
(b)	Address of issuer's principal executive offices: 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065
Item 2.
(a)	Name of person filing: Thomas A. Satterfield, Jr.
(b)	Address or principal business office or, if none, residence: 15 Colley Cove Drive Gulf Breeze, FL 32561
(c)	Citizenship: Incorporated by reference from Item 4 of the Cover Page.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 19249H103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Incorporated by reference from Item 9 of the Cover Page.
(b)	Percent of class: Incorporated by reference from Item 11 of the Cover Page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Incorporated by reference from Item 5 of the Cover Page.
	(ii) Shared power to vote or to direct the vote: Incorporated by reference from Item 6 of the Cover Page.
	(iii) Sole power to dispose or to direct the disposition of: Incorporated by reference from Item 7 of the Cover Page.
	(iv) Shared power to dispose or to direct the disposition of: Incorporated by reference from Item 8 of the Cover Page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 115,000 shares are held jointly with Rebecca S. Satterfield, Mr. Satterfield's spouse; 800,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 2,100,000 shares are held by Caldwell Mill Opportunity Fund, which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 1,750,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield. Additionally, Mr. Satterfield has limited powers of attorney for voting and disposition purposes with respect to the following shares: Thomas A. Satterfield, Sr. (400,000 shares); Rebecca S. Satterfield (100,000); Parker Satterfield (32,000 shares); Jeanette Satterfield Kaiser (230,000 shares); Richard W. Kaiser (100,000 shares); Parker Little Trust (20,000 shares); Lola Little Trust (20,000 shares); Milyn Little (25,000); Henry Beck (75,000 shares); Pam Beck (20,000); John and Angela Picton (100,000); Christy Beard (20,000); Paula and Gene Colley (75,000); Glenna and Jesse Colley (75,000); Alex Flannery (4,000); and Camile Richards (4,000). These individuals and entities have the right to receive or the power to direct the receipt of the proceeds from the sale of their respective shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Thomas A. Satterfield, Jr.

Signature:	/s/ Thomas A. Satterfield, Jr.
Name/Title:	Thomas A. Satterfield, Jr.
Date:	04/29/2026